scholarly journals Clinically Relevant Outcome Research in Individual Psychotherapy New models guide the researcher and clinician

1994 ◽  
Vol 165 (1) ◽  
pp. 4-8 ◽  
Author(s):  
Kenneth I. Howard ◽  
David E. Orlinsky ◽  
Robert J. Lueger

How can we design relevant psychotherapy research? The answer must be shaped by the objectives and potential consumers of such research. For over 40 years, “does psychotherapy work?” (Eysenck, 1952) held the attention of psychotherapy researchers, and randomised clinical trial methodology seemed the most appropriate empirical option for answering this question. There are now well over 500 studies that attest to the efficacy of psychotherapy (see Smith et al, 1980; Shapiro & Shapiro, 1982; Lipsey & Wilson, 1993, for meta-analytic research summaries); it seems that psychotherapy is one of the best documented medical interventions in history. But the conclusion that psychotherapy “works” is akin to finding that antibiotics “work”. We are left with the daunting task of determining which of the wide variety of treatments (psychotherapies, antibiotics) are appropriate for which variety of illnesses (psychopathologies, infections). Morris Parloff (1982) warned us of this need for specificity in his classic article, “Bambi meets Godzilla”, but our preoccupation with documenting the efficacy of psychotherapy has only recently abated enough to mount empirical studies of such specificity.

1995 ◽  
pp. 407-417 ◽  
Author(s):  
T. L. Munsat ◽  
D. Hollander ◽  
L. Finison

2018 ◽  
Vol 149 (3) ◽  
pp. 605-611 ◽  
Author(s):  
Jubilee Brown ◽  
R. Wendel Naumann ◽  
William E. Brady ◽  
Robert L. Coleman ◽  
Kathleen N. Moore ◽  
...  

2019 ◽  
Vol 3 (3) ◽  
pp. 269-279
Author(s):  
Kelley C. O’Donnell ◽  
Sarah E. Mennenga ◽  
Michael P. Bogenschutz

Background and aims Given the enormous global burden of depressive illness, there is an urgent need to develop novel and more effective treatments for major depressive disorder (MDD). Recent findings have suggested that psychedelic drugs may have a role in the treatment of depressive symptoms, and a number of groups are in the process of developing protocols to study this question systematically. Given the subjective quality of both the psychedelic experience and depressive symptomatology, great care must be taken when designing a protocol to study the clinical efficacy of psychedelic drugs. This study will discuss many factors to consider when designing a clinical trial of psilocybin for MDD. Methods We provide a thorough review of pertinent research into antidepressant clinical trial methodology and review practical considerations that are relevant to the study of psychedelic-assisted treatment for depression. Results We discuss participant selection (including diagnostic accuracy, exclusion criteria, characteristics of the depressive episode, and the use of concurrent medications), study interventions (including dosing regimens, placebo selection, non-pharmacological components of treatment, and the importance of blinding), trial duration, outcome measures, and safety considerations. Conclusions Careful and transparent study design and data analysis will maximize the likelihood of generating meaningful, reproducible results, and identifying a treatment-specific effect. Meeting the highest standards for contemporary trial design may also broaden the acceptance of psychedelic research in the scientific community at large.


Neurology ◽  
1997 ◽  
Vol 48 (6) ◽  
pp. 1743-1748 ◽  
Author(s):  
L. E. Chambless ◽  
J. D. Hosking ◽  
R. Kronmal ◽  
G. Howard ◽  
V. J. Howard

1992 ◽  
Vol 63 (12s) ◽  
pp. 1064-1071 ◽  
Author(s):  
Kenneth S. Kornman ◽  
Michael G. Newman ◽  
Samuel Holtzman ◽  
James E. Matheson

Author(s):  
Katharine A. Nicholson ◽  
James D. Berry

The current state of amyotrophic lateral sclerosis (ALS) trial design is best understood within the context of ALS research over the past quarter century. Before the early 1990s, trials in ALS were typically small and clinical trial methodology was less rigorous than it is today. With the discovery of the SOD1 gene mutation in the early 1990s, a new era of excitement and innovation for ALS research began. Since then, the number of ALS trials has steadily increased and trial design and methodology has become increasingly sophisticated.


Sign in / Sign up

Export Citation Format

Share Document